As a very 1st project in Qing’s PhD training, he demonstrated that cancer-driving mutant proteins could be directly detected and quantified by mass spectrometry in cancer cells or body fluids—establishing a new measurement layer beyond genomics and laying the technological foundation for next-generation precision oncology.
First Platform for Quantifying Mutant Proteins in Cancer
Building on the translational vision that emerged during his early training in the laboratory of Bert Vogelstein at Johns Hopkins University School of Medicine, Qing Wang began developing one of the first systematic methods to directly measure mutation-derived proteins in human cancers.
At the time, cancer genomics was rapidly revealing the genetic mutations that drive tumor development. Landmark sequencing studies had identified key oncogenes and tumor suppressor genes such as KRAS and TP53 across many cancer types. Yet a major gap remained: although mutations could be detected at the DNA level, there were few technologies capable of verifying whether those mutations produced detectable proteins inside real biological samples.
Wang recognized that this gap represented a critical bottleneck for translational oncology. If mutations could be directly measured at the protein level, researchers and clinicians could gain a new layer of molecular evidence linking genomic alterations to functional disease biology.
Building the First Targeted Mutant-Protein Detection Strategy
To address this challenge, Wang pioneered a targeted mass spectrometry strategy designed to detect mutation-specific peptides derived from cancer driver genes. By combining genomic mutation information with highly specific peptide assays, the method allowed mutant proteins to be detected and quantified in complex biological samples.
This work culminated in one of the earliest demonstrations that mutant proteins could be directly measured using targeted mass spectrometry, establishing a new framework for validating genomic discoveries at the proteomic level.
The results were later reported in the landmark study:
“Mutant proteins as cancer-specific biomarkers.”
Published in Proceedings of the National Academy of Sciences of the United States of America in 2011.
The study demonstrated that mutant proteins derived from cancer driver genes could serve as highly specific biomarkers for cancer detection and disease monitoring. Importantly, it showed that targeted proteomics could achieve the sensitivity and specificity required to distinguish mutant peptides from their wild-type counterparts.
A New Measurement Layer for Precision Oncology
This work represented one of the earliest efforts to systematically integrate genomics with targeted proteomics for cancer biomarker discovery. It introduced the concept that genomic mutations could be translated into measurable peptide targets—creating a new measurement layer that bridges DNA sequencing and functional protein biology.
The approach laid the technical and conceptual foundation for future advances in:
- mutation-specific biomarker detection
- neoantigen identification
- quantitative validation of genomic discoveries
- precision immunotherapy target discovery
Over the following decade, these ideas would evolve into increasingly powerful proteomics platforms capable of measuring thousands of proteins across large clinical cohorts.
From Mutant Protein Detection to Complete360®
Looking back, this early work marked an important milestone in Wang’s scientific journey. It demonstrated that clinical proteomics could validate and extend genomic discoveries, opening the door to a new generation of molecular diagnostics.
The strategy of translating genomic mutations into quantifiable peptide signals ultimately became one of the conceptual building blocks for the Complete360® platform, which now enables ultra-deep measurement of thousands of proteins across human disease samples.
What began as a targeted effort to measure a handful of mutant proteins would eventually grow into a platform capable of systematically measuring the human proteome at clinical scale.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.